Malcolm Boyce

8PUBLICATIONS
12CO-AUTHORS
Food properties (incl. characteristics and health benefits)PharmacogenomicsChemotherapyApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Applications in health
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|Dec 31, 2024
A randomized, double-blind, placebo-controlled, multiple dose, parallel study to investigate the effects of a cathepsin S inhibitor in celiac disease.

Darren Bentley, Marie Mannino, Marianne Manchester

|Jun 15, 2023
Neuroendocrine mechanism of gastric acid secretion: Historical perspectives and recent developments in physiology and pharmacology.

Duan Chen, Susan J Hagen, Malcolm Boyce

|Apr 14, 2023
Ensovibep, a SARS-CoV-2 antiviral designed ankyrin repeat protein, is safe and well tolerated in healthy volunteers: Results of a first-in-human, ascending single-dose Phase 1 study.

Nina Stojcheva, Stacy Gladman, Marianne Soergel

|Jan 15, 2021
ONO-7684 a novel oral FXIa inhibitor: Safety, tolerability, pharmacokinetics and pharmacodynamics in a first-in-human study.

Dominic Beale, Jeremy Dennison, Malcolm Boyce

|Aug 28, 2020
Immunogenicity of an adalimumab biosimilar, FKB327, and its reference product in patients with rheumatoid arthritis.

Rieke Alten, Colin Markland, Malcolm Boyce

|Sep 16, 2017
Regulatory experience of TOPS: an internet-based system to prevent healthy subjects from over-volunteering for UK clinical trials.

C Allen, G Francis, J Martin

Pageof 2

Frequent Collaborators

1 joint publications

Rieke Alten

1 joint publications

Colin Markland

1 joint publications

Kazuki Kawakami

1 joint publications

Rafael Muniz